Juvenescence AI to develop first compounds generated by Insilico’s deep-learned drug discovery engines

Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited.